BICO Group AB buy Max1111
Start price
17.07.23
/
100%
€3.83
Target price
17.07.25
€20.00
Performance (%)
-27.36%
End price
27.01.25
€2.78
Summary
This prediction ended on 27.01.25 with a price of €2.78. The prediction for BICO Group AB disappointed with a performance of -27.36%. Max1111 has 100% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| BICO Group AB | -5.685% | -5.685% | -42.316% |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% |
According to Max1111 what are the pros and cons of BICO Group AB for the foreseeable future?
Pros
EBIT growth > 30% per year expected
Capable Management
Strong uniques
High Investments for future growth
Revenue growth > 30% per year expected
Leading role in innovation
Growths much faster than the competition
Market Leader or Top 3
Known brand
Very Future proof/growth oriented business model
Cons
Increased challenges to pay loans and raise capital
Risky balance sheet
ROE lower than 10% per year
Comments by Max1111 for this prediction
In the thread Cellink Ab diskutieren
Kursziel gesetzt auf 20,0
Führend im Bioprinting; 10 % Beteiligung von Sartorius<; momentan noch nicht Profitabel.
DYOR
https://bico.com/
DYOR
https://bico.com/